Australia: A more transparent Therapeutic Goods Administration?

Last Updated: 25 July 2011
Article by Jessica Kinny and Wendy Blacker

On 20 July 2011 the Australian Government released a report that could be the catalyst for greater transparency in the operation and regulation of the therapeutic goods industry.

On 16 November 2010 Parliamentary Secretary for Health and Ageing, Catherine King, announced that a review was to be commissioned in response to community concern about the lack of information made available by the Therapeutic Goods Administration (TGA).  The focus of the review was to improve the TGA's transparency to ensure that the public is better informed about the TGA's regulatory processes and the benefits and risk of therapeutic goods. 

The review was undertaken by the Therapeutic Goods Administration Transparency Review Panel (the Panel), chaired by Professor Dennis Pearce.  There were 13 members on the Panel; each member representing the main stakeholder groups of consumers, health practitioners, the rural health sector and the therapeutic goods industry.  The five members representing the therapeutic goods industry represented the following sectors: prescription medicines; generic prescription medicines; over-the-counter medicines; complementary medicines; and medical devices.

The Panel commenced operation on 10 December 2010 with a view to providing a report by 29 April 2011.  That date was extended to 30 June 2011 when the size of the task, and the extent of the public interest in the review, was realised. 

Executive summary: key recommendations of the Panel

The consultations carried out by the Panel during the review highlighted the need for the TGA to devise and implement strategies to improve communications between the TGA and its key stakeholders.  

A copy of the Review Report, which contains detailed information regarding each recommendation, is available here.  An executive summary of the unanimous recommendations of the Panel are contained in the Final Report titled 'Review to improve the transparency of the Therapeutic Goods Administration' (the Report) and are as follows.

Recommendations for raising stakeholder involvement in the TGA

1.       The TGA establish an Australian Therapeutic Goods Advisory Council made up of representatives of major stakeholder groups that holds an oversight role in the implementation, ongoing monitoring and evaluation of the recommendations of the Report.

2.       The TGA develop, implement and publish consultation principles to ensure regulatory transparency and accountability.

3.       The TGA develop and implement a comprehensive communication strategy geared to inform and educate the community and stakeholders.  The establishment of a TGA communications team was recommended to achieve this objective. 

4.       The TGA work transparently with other key providers of information to enhance the information available to stakeholders and members of the community.

5.       The TGA develop a plan to ensure information on the key public access portal, the TGA website, is current, accurate and relevant and meets the needs of its audiences.

6.       The TGA provide user-friendly information on the risk based framework under which it operates; particularly information on the difference between registered and listed therapeutic goods and their processes of evaluation.

7.       The TGA implement mechanisms to inform the public that listed medicines are not evaluated for effectiveness by the TGA prior to market.

8.       The TGA provide clear information on the role of its statutory advisory committees, and adopt a consistent and transparent approach to the publication of information from those committees.

9.       The TGA improve access to and quality of information on the regulation of advertising of therapeutic goods.  This is to include information on the complaint process and the outcomes of complaints.

10.   The TGA, in conjunction with key stakeholders, develop and publish agreed key performance indicators on the TGA's organisational effectiveness and operational efficiency.

Recommendations for improving market authorisation processes

11.   The TGA develop and publish a policy on the disclosure of commercially confidential information, noting significant issues for each therapeutic product type.  The policy is to take into account the practices followed by comparable international regulators.

12.   The TGA explore ways of explaining its various regulatory processes to the public and adopt publication principles on the outcomes of application assessments using as an exemplar the Australian Public Assessment Reports.

13.   The TGA assess and report on the feasibility of developing an online system for the submission and tracking of all applications for assessment.  This system is to include a means of allowing the sponsor to track the progress of an application.

14.   The TGA work with stakeholders to improve labelling and packaging requirements.  The purpose of implementing this recommendation will be to educate consumers and health practitioners so they may make informed decisions about the quality use of therapeutic goods.

Recommendations to improve monitoring and compliance

15.   The TGA conduct, and report on, a feasibility study into the development of an early post marketing risk communication scheme for therapeutic goods.  International models are to be considered when devising the scheme.

16.   The TGA actively promote the distribution of therapeutic goods safety information and consider ways of improving the timely communication of alerts and recalls to health practitioners and consumers.

17.   The TGA explore ways of maintaining the currency of Consumer Medicine Information and Approved Product Information.

18.   The TGA progressively develop and implement a system to publish the outcomes of investigations and compliance actions taken.

19.   The TGA more effectively facilitate the recognition and reporting of adverse events by health practitioners and consumers, and promote the adverse event reporting system.

20.   The TGA make its Adverse Events Database available to, and searchable by, the public in a manner that supports the quality use of therapeutic goods.

21.   The TGA work with State and Territory Governments, stakeholders, and other relevant agencies, to improve the visible management of adverse event reporting in support of consumer safety and consistent with the finding of the Horvath Review into Immunisation.

The Government will now consider the Review Panel Report and provide a formal response to these recommendations.

contact us
For more information, please contact:


Wendy Blacker

t (02) 9931 4922



The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Related Topics
Related Articles
Up-coming Events Search
Font Size:
Mondaq on Twitter
Mondaq Free Registration
Gain access to Mondaq global archive of over 375,000 articles covering 200 countries with a personalised News Alert and automatic login on this device.
Mondaq News Alert (some suggested topics and region)
Select Topics
Registration (please scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions